What is CUSIP 045396108?

CUSIP 045396108 is the security identifier used in SEC filing datasets for ASMB - ASSEMBLY BIOSCIENCES, INC. - Common Stock, par value $0.001.

Security Snapshot

ASSEMBLY BIOSCIENCES, INC. - Common Stock, par value $0.001 (ASMB) Institutional Ownership

Q: Who owns ASMB - ASSEMBLY BIOSCIENCES, INC. - Common Stock, par value $0.001 based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

CUSIP: 045396108

13F Institutional Holders and Ownership History from Q3 2014 to Q1 2024

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period

Security type / class: Equity / Common Stock, par value $0.001
Symbol: ASMB on Nasdaq
Shares outstanding: 19,829,040

13F Shares, Excluding Options vs Price

13F Value, Excluding Options

Total Investors

Key facts

ASMB - ASSEMBLY BIOSCIENCES, INC. - Common Stock, par value $0.001 is tracked under CUSIP 045396108.
Latest finished 13F holder period is not available.
2 significant owners is listed from Schedule 13D/13G reporting.

Change

Holder count moved from 42 to 0 between Q4 2023 and Q1 2024.
SEC-reported value moved from $7,090,909 to $0.

Research use

You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

045396108

Latest holder period

n/a

13F holders

13D/G owners

CIK / CUSIP context first

ASMB full holder history ASSEMBLY BIOSCIENCES, INC. SEC filings ASSEMBLY BIOSCIENCES, INC. company facts ASSEMBLY BIOSCIENCES, INC. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 045396108:

Q1 2024 (0 holders) Q4 2023 (42 holders) Q3 2023 (32 holders) Q2 2023 (31 holders) Q1 2023 (37 holders) Q4 2022 (38 holders) Q3 2022 (47 holders) Q2 2022 (51 holders) Q1 2022 (52 holders) Q4 2021 (57 holders)

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows

Security

ASMB

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
GILEAD SCIENCES, INC.	25%	-13%			4,977,089	+10%	GILEAD SCIENCES, INC.	22 May 2026
Paradigm Biocapital Advisors LP	5.4%				865,251		Paradigm BioCapital Advisors LP	04 May 2026

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods

Latest

n/a

Rows shown

1-25 of 39

Period	13F Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2024 Q1	0	$0	-$7,090,883	$0	$0		0
2023 Q4	8,647,319	$7,090,909	-$888,258	$5,085	$2,460	$0.82	42
2023 Q3	9,538,435	$8,441,336	-$822,987		$9,381	$0.88	32
2023 Q2	10,465,062	$12,032,628	-$1,413,281		$17,480	$1.15	31
2023 Q1	12,058,487	$10,132,844	-$2,696,808		$22,775	$0.84	37
2022 Q4	14,193,683	$18,446,999	-$3,479,618		$23,270	$1.30	38
2022 Q3	16,595,417	$27,215,067	-$1,058,512		$35,000	$1.64	47
2022 Q2	17,189,015	$36,094,086	-$3,856,015		$164,000	$2.10	51
2022 Q1	19,078,839	$39,299,944	-$9,004,415	$0	$70,000	$2.06	52
2021 Q4	23,096,231	$53,810,453	-$9,786,082	$86,000	$65,000	$2.33	57
2021 Q3	22,706,616	$79,015,136	-$15,483,325	$933,000	$851,000	$3.48	61
2021 Q2	27,092,112	$105,110,485	-$6,950,361	$1,328,000	$1,149,000	$3.88	87
2021 Q1	27,158,674	$124,930,551	+$3,461,631	$425,000	$379,000	$4.60	102
2020 Q4	26,661,326	$161,302,039	-$148,788,454	$127,000	$338,000	$6.05	106
2020 Q3	30,096,975	$494,769,297	+$965,633		$750,000	$16.44	115
2020 Q2	29,993,173	$700,372,173	+$25,372,004	$0	$529,000	$23.32	103
2020 Q1	28,961,280	$429,566,715	+$7,108,278	$3,045,000	$2,598,000	$14.83	96
2019 Q4	28,128,251	$575,504,046	+$162,191,719	$3,302,000	$3,955,000	$20.46	99
2019 Q3	20,717,323	$203,852,941	-$9,083,327	$102,000	$5,409,000	$9.83	96
2019 Q2	21,081,214	$285,953,531	-$38,445,831	$0	$7,581,000	$13.49	105
2019 Q1	22,086,821	$435,072,882	+$11,598,737	$654,000	$3,882,000	$19.69	100
2018 Q4	21,336,229	$482,552,988	-$22,408,761	$226,000	$238,000	$22.62	105
2018 Q3	21,451,389	$796,704,124	+$177,939,690	$2,010,000	$6,634,000	$37.14	110
2018 Q2	16,619,055	$651,643,809	+$19,143,017	$4,218,000	$6,697,000	$39.21	103
2018 Q1	16,057,360	$789,004,865	+$27,408,726	$7,981,000	$19,180,000	$49.14	105